Sales of vaccines in 2008 totaled $19.2bn (€13.8bn), an increase of 21.5 per cent on the previous year, and this upwards trend is predicted to continue as more nations establish educational programmes to promote immunisation.
Bruce Carlson, publisher of Kalorama Information, added: "New products and better-than-expected profits, as well as merger activity, have transformed the vaccine marketplace.
"Continued sales of influenza and cervical cancer vaccines have provided a foundation for growth in the adult market. Meanwhile, the pediatric market was fueled by several major products including Wyeth's pneumococcal vaccines Prevnar and Merck's new rotavirus vaccine TotaTeq."
